A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? ; day:7 ; month:11 ; year:2023 ; pages:1-12
Cancer chemotherapy and pharmacology ; (7.11.2023), 1-12
- Creator
-
Ginzac, Angeline
Thivat, Emilie
Petorin, Caroline
Richard, Damien
Herviou, Pauline
Molnar, Ioana
Devaud, Hervé
Creveaux, Isabelle
Ferrer, Florent
Authier, Nicolas
Jary, Marine
Pezet, Denis
Durando, Xavier
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-023-04603-x
- URN
-
urn:nbn:de:101:1-2024012409164163180481
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ginzac, Angeline
- Thivat, Emilie
- Petorin, Caroline
- Richard, Damien
- Herviou, Pauline
- Molnar, Ioana
- Devaud, Hervé
- Creveaux, Isabelle
- Ferrer, Florent
- Authier, Nicolas
- Jary, Marine
- Pezet, Denis
- Durando, Xavier
- SpringerLink (Online service)
Other Objects (12)
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
CrcZ
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
CRC (Cyclic Redundancy Check)
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
Children's Resource Centre, Kapstadt (CRC)
Report: Cultural Research Centre (CRC)
Fast and Flexible CRC Calculation
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
CrcZ
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
CRC (Cyclic Redundancy Check)
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
Children's Resource Centre, Kapstadt (CRC)
Report: Cultural Research Centre (CRC)
Fast and Flexible CRC Calculation
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
CrcZ
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
CRC (Cyclic Redundancy Check)
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
Children's Resource Centre, Kapstadt (CRC)
Report: Cultural Research Centre (CRC)